Pharmacokinetics of Mycophenolate Mofetil in Hematopoietic Stem Cell Transplant Recipients

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Therapeutic Drug Monitoring

• Publication date

  2007-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/FTD.0b013e31805d8816PMID 17529894
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Highly Variable Mycophenolate Mofetil Bioavailability Following Nonmyeloablative Hematopoietic Cell Transplantation

  2007cited by this paper
• Cyclosporine Interacts with Mycophenolic Acid by Inhibiting the Multidrug Resistance‐Associated Protein 2

  2005cited by this paper
• Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Recipients

  2005cited by this paper
• A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.

  2005cited by this paper
• Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation.

  2005influential reference
• Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation

  2005influential reference
• Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil.

  2005cited by this paper
• Free Mycophenolic Acid Should Be Monitored in Renal Transplant Recipients with Hypoalbuminemia

  2004cited by this paper
• A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.

  2004cited by this paper
• A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation

  2004cited by this paper
• Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total mycophenolic acid.

  2004cited by this paper
• Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration1

  2003cited by this paper
• Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio

  2003cited by this paper
• Immunosuppression: practice and trends

  2003cited by this paper
• Twelve‐Month Evaluation of the Clinical Pharmacokinetics of Total and Free Mycophenolic Acid and Its Glucuronide Metabolites in Renal Allograft Recipients on Low Dose Tacrolimus in Combination with Mycophenolate Mofetil

  2003cited by this paper
• HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.

  2003cited by this paper
• Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring Strategies

  2003cited by this paper
• Pharmacokinetics and Protein Adduct Formation of the Pharmacologically Active Acyl Glucuronide Metabolite of Mycophenolic Acid in Pediatric Renal Transplant Recipients

  2002cited by this paper
• Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients

  2002cited by this paper
• The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy.

  2002cited by this paper
• Current Issues in Therapeutic Drug Monitoring of Mycophenolic Acid: Report of a Roundtable Discussion

  2001cited by this paper
• Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation

  2001influential reference
• Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit.

  2000cited by this paper
• Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects?

  2000cited by this paper
• Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite.

  2000cited by this paper
• Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.

  2000cited by this paper
• Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation : Implications for therapeutic drug monitoring

  2000cited by this paper
• Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection.

  2000cited by this paper
• Mycophenolic Acid Area under the Curve Values in African American and Caucasian Renal Transplant Patients Are Comparable

  2000cited by this paper
• The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients

  1999cited by this paper
• Identification of glucoside and carboxyl‐linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil

  1999cited by this paper
• Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.

  1999cited by this paper
• A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

  1998cited by this paper
• Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation.

  1998cited by this paper
• Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.

  1998cited by this paper
• Clinical Pharmacokinetics of Mycophenolate Mofetil

  1998influential reference
• Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts.

  1998cited by this paper
• Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure.

  1998cited by this paper
• Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups.

  1997cited by this paper
• Pharmacokinetics and Bioavailability of Mycophenolate Mofetil in Healthy Subjects after Single‐Dose Oral and Intravenous Administration

  1996cited by this paper
• Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics.

  1995cited by this paper
• Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.

  1993cited by this paper
• Clinical Pharmacokinetics: Concepts and applications.

  1983cited by this paper

• Mycophenolate mofetil‐induced colitis versus colonic graft‐versus‐host disease: a comparative histologic study with artificial intelligence model development

  2025cites this paper
• Body Surface Area-Based Dosing of Mycophenolate Mofetil in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Prospective Population Pharmacokinetic Study

  2023cites this paper
• Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

  2021cites this paper
• Drug monitoring for mycophenolic acid in graft‐vs‐host disease prophylaxis in cord blood transplantation

  2020cites this paper
• Kobe University Repository : Kernel タイトル Tit le Populat ion pharmacokinet ics and pharmacodynamics of mycophenolic acid using the prospect ive data in pat ients undergoing hematopoiet

  2020cites this paper
• Population pharmacokinetics and Bayesian estimators for intravenous mycophenolate mofetil in haematopoietic stem cell transplant patients

  2020cites this paper
• A Limited Sampling Strategy for Therapeutic Drug Monitoring of Mycophenolate Mofetil for Prophylaxis of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation

  2020cites this paper
• Pharmacokinetics of Basiliximab for the Prevention of Graft‐versus‐Host Disease in Patients Undergoing Hematopoietic Cell Transplantation with Minimal‐Intensity Cyclophosphamide and Fludarabine

  2019cites this paper
• Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients

  2018cites this paper
• Population pharmacokinetics and pharmacodynamics of mycophenolic acid using the prospective data in patients undergoing hematopoietic stem cell transplantation

  2018cites this paper
• Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients

  2017cites this paper
• Pharmacokinetic Variability of Mycophenolic Acid in Pediatric and Adult Patients With Hematopoietic Stem Cell Transplantation

  2016cites this paper
• Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II

  2016cites this paper
• Le dosage sanguin du mycophenolate mofetil chez les greffés rénaux du service de néphrologie du CHU de Tlemcen

  2016cites this paper
• A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.

  2016cites this paper
• Optimizing drug therapy in pediatric SCT: Focus on pharmacokinetics

  2015cites this paper
• Monitoring mycophenolate mofetil is necessary for the effective prophylaxis of acute GVHD after cord blood transplantation

  2015cites this paper
• Interleukin-2-stimulated natural killer cells are less susceptible to mycophenolate mofetil than non-activated NK cells: possible consequences for immunotherapy

  2014cites this paper
• Découverte de nouveaux marqueurs pharmacogénomiques de la maladie du greffon contre l'hôte en transplantation de cellules souches hématopoïétiques

  2014cites this paper
• Prolonged Influenza Virus Shedding and Emergence of Antiviral Resistance in Immunocompromised Patients and Ferrets

  2013cites this paper
• Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil

  2013cites this paper
• Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors

  2013cites this paper
• Immunosuppressive Agents and Monitoring in Long‐Term Survivors

  2013cites this paper
• Mycophenolate mofetil: fully utilizing its benefits for GvHD prophylaxis

  2012influential citation
• [Level of evidence for therapeutic drug monitoring of MPA in hematopoietic stem cell transplantation].

  2011cites this paper
• Mycophenolate monitoring in liver, thoracic, pancreas, and small bowel transplantation: a consensus report.

  2011cites this paper
• Niveau de preuve du suivi thérapeutique pharmacologique de l’acide mycophénolique administré pour la prévention des réactions du greffon contre l’hôte au cours des greffes de cellules souches avec un conditionnement réduit

  2011cites this paper
• [Not Available].

  2011cites this paper
• Mycophenolic acid trough level monitoring: relevance in acute and chronic graft versus host disease and its relation with albumin

  2011cites this paper
• Pharmacokinetic modelling and development of Bayesian estimators for the therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic cell transplantation

  2010cites this paper
• Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network.

  2010cites this paper
• Differences in Clearance of Mycophenolic Acid Among Renal Transplant Recipients, Hematopoietic Stem Cell Transplant Recipients, and Patients With Autoimmune Disease

  2010influential citation
• Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis.

  2010cites this paper
• Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic stem cell transplantation as preemptive therapy for severe graft-versus-host disease.

  2009cites this paper
• Mycophenolate mofetil in dermatology.

  2009cites this paper
• Inflammation and its echo in atherosclerosis

  2009cites this paper
• Measurement of Total and Unbound Mycophenolic Acid and Its Glucuronide by LC Coupled with MS. Application to a Pharmacokinetic Study of Mycophenolate Mofetil in Patients with Autoimmune Diseases

  2009cites this paper
• Pharmacokinetics of mycophenolic acid administered 3 times daily after hematopoietic stem cell transplantation with reduced-intensity regimen.

  2009cites this paper
• Pharmacokinetic Modelling and Development of Bayesian Estimators for Therapeutic Drug Monitoring of Mycophenolate Mofetil in Reduced-Intensity Haematopoietic Stem Cell Transplantation

  2009cites this paper
• Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation

  2009cites this paper
• Impact of Calcineurin Inhibitors on Urinary Excretion of Mycophenolic Acid and Its Glucuronide in Kidney Transplant Recipients

  2009influential citation
• Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantation

  2008cites this paper
• Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation

  2008cites this paper
• Pharmacocinétique du mofétilmycophénolate en greffe hématopoïétique : étude d’un cas pédiatrique

  2008cites this paper
• Higher Mycophenolate Dose Requirements in Children Undergoing Hematopoietic Cell Transplant (HCT)

  2008cites this paper
• Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation

  2008influential citation